Docosahexaenoic acid in ARSACS: observations in two patients.
Ivana RiccaAlessandra TessaRosanna TrovatoGiacomo Maria BacciFilippo Maria SantorelliPublished in: BMC neurology (2020)
DHA was safe over a long period and well-tolerated by the two patients; both showed a stabilization of clinical symptoms, rather than the expected deterioration, warranting additional investigations in patients with mutations in SACS.